Xenon Pharmaceuticals Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Xenon Pharmaceuticals de 15.3% y 74.6% por año respectivamente. Se prevé que el BPA crezca en un 18% al año. Se espera que la rentabilidad financiera sea de -56.8% en 3 años.
Información clave
15.3%
Tasa de crecimiento de los beneficios
18.0%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 27.1% |
| Tasa de crecimiento de los ingresos | 74.6% |
| Rentabilidad financiera futura | -56.8% |
| Cobertura de analistas | Good |
| Última actualización | 16 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 44 | -329 | -263 | -289 | 13 |
| 12/31/2025 | 5 | -283 | -190 | -251 | 16 |
| 12/31/2024 | 0 | -237 | -205 | -197 | 16 |
| 6/30/2024 | N/A | -199 | -157 | -154 | N/A |
| 3/31/2024 | N/A | -189 | -158 | -154 | N/A |
| 12/31/2023 | N/A | -182 | -151 | -145 | N/A |
| 9/30/2023 | N/A | -175 | -150 | -143 | N/A |
| 6/30/2023 | 0 | -165 | -137 | -131 | N/A |
| 3/31/2023 | 1 | -148 | -119 | -114 | N/A |
| 12/31/2022 | 9 | -126 | -101 | -98 | N/A |
| 9/30/2022 | 13 | -113 | -88 | -86 | N/A |
| 6/30/2022 | 21 | -91 | -73 | -71 | N/A |
| 3/31/2022 | 23 | -83 | -69 | -67 | N/A |
| 12/31/2021 | 18 | -81 | -72 | -70 | N/A |
| 9/30/2021 | 20 | -66 | -64 | -62 | N/A |
| 6/30/2021 | 18 | -59 | -61 | -58 | N/A |
| 3/31/2021 | 29 | -37 | -58 | -56 | N/A |
| 12/31/2020 | 32 | -29 | -51 | -48 | N/A |
| 9/30/2020 | 30 | -28 | -18 | -15 | N/A |
| 6/30/2020 | 27 | -28 | -13 | -11 | N/A |
| 3/31/2020 | 14 | -38 | -11 | -9 | N/A |
| 12/31/2019 | 7 | -42 | -6 | -5 | N/A |
| 9/30/2019 | 4 | -39 | -33 | -32 | N/A |
| 6/30/2019 | N/A | -44 | -39 | -38 | N/A |
| 3/31/2019 | N/A | -42 | -36 | -35 | N/A |
| 12/31/2018 | N/A | -34 | -35 | -35 | N/A |
| 9/30/2018 | 0 | -34 | -35 | -34 | N/A |
| 6/30/2018 | 0 | -27 | -30 | -29 | N/A |
| 3/31/2018 | 0 | -27 | N/A | -30 | N/A |
| 12/31/2017 | 0 | -31 | N/A | -29 | N/A |
| 9/30/2017 | 1 | -29 | N/A | -27 | N/A |
| 6/30/2017 | 1 | -29 | N/A | -22 | N/A |
| 3/31/2017 | 1 | -27 | N/A | -21 | N/A |
| 12/31/2016 | 2 | -23 | N/A | -20 | N/A |
| 9/30/2016 | 5 | -21 | N/A | -20 | N/A |
| 6/30/2016 | 9 | -17 | N/A | -21 | N/A |
| 3/31/2016 | 12 | -10 | N/A | -17 | N/A |
| 12/31/2015 | 16 | -16 | N/A | -18 | N/A |
| 9/30/2015 | 17 | -2 | N/A | -16 | N/A |
| 6/30/2015 | 26 | 5 | N/A | -5 | N/A |
| 3/31/2015 | 27 | 4 | N/A | -4 | N/A |
| 12/31/2014 | 28 | 13 | N/A | 0 | N/A |
| 9/30/2014 | 29 | 6 | N/A | 1 | N/A |
| 6/30/2014 | 27 | 4 | N/A | -1 | N/A |
| 3/31/2014 | 27 | 4 | N/A | -1 | N/A |
| 12/31/2013 | 27 | 4 | N/A | -3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que XENE siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que XENE siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que XENE siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (74.6% al año) de XENE crezcan más rápidamente que los del mercado US (8.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (74.6% al año) de XENE crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: XENE se prevé que no sea rentable en 3 años.